A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewFinal results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial.Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene.First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
P2860
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Phase II study of cetuximab ...... metastatic colorectal cancer.
@en
A Phase II study of cetuximab
@nl
type
label
A Phase II study of cetuximab ...... metastatic colorectal cancer.
@en
A Phase II study of cetuximab
@nl
prefLabel
A Phase II study of cetuximab ...... metastatic colorectal cancer.
@en
A Phase II study of cetuximab
@nl
P2093
P2860
P1476
A Phase II study of cetuximab ...... y metastatic colorectal cancer
@en
P2093
Heung Moon Chang
Jae Lyun Lee
Jung Shin Lee
Min Hee Ryu
Min Kyoung Kim
Sun Jin Sym
Sung Sook Lee
Tae Won Kim
Yoon Koo Kang
P2860
P304
P356
10.3346/JKMS.2007.22.S.S98
P478
P50
P577
2007-09-01T00:00:00Z